# Corticosteroid Injections in Dogs: Indications, Risks, and Monitoring


## Key Takeaways

- Injectable corticosteroids are indicated for noninfectious inflammatory conditions, immune-mediated diseases, and certain dermatopathies, offering rapid onset of action via parenteral absorption, typically within hours to 24 hours, bypassing first-pass hepatic metabolism.
- Drug selection hinges on ester formulation, which dictates duration of action: short-acting (e.g., prednisolone, methylprednisolone) provide effects for approximately 24-72 hours, while repository formulations (e.g., triamcinolone acetonide, dexamethasone phenylpropionate) can suppress the hypothalamic-pituitary-adrenal axis for 2-4 weeks.
- Major acute risks include gastrointestinal ulceration, pancreatitis, hyperglycemia, and behavioral changes, while chronic risks encompass iatrogenic hyperadrenocorticism, hepatopathy, muscle wasting, and immunosuppression, necessitating careful case selection and risk-benefit assessment.
- Contraindications include active systemic infection, corneal ulceration, and known hypersensitivity; relative contraindications like diabetes mellitus, pregnancy, and renal disease require significant caution and risk mitigation strategies.
- Monitoring is crucial, with baseline assessments including body weight, blood pressure, urinalysis, and serum biochemistry (glucose, liver enzymes), followed by clinical response checks at 7-14 days and reassessment of biochemistry if repeat dosing is planned.
- The decision to inject versus prescribe oral corticosteroids involves owner compliance, gastrointestinal tolerance, and the need for rapid onset or sustained effect, with injectables offering predictable bioavailability but lacking the ability to be rapidly withdrawn in case of adverse reactions.

---

Injectable corticosteroids remain a common intervention in canine practice, yet their use generates persistent questions about appropriate case selection, comparative drug choice, and the balance between anti-inflammatory benefit and systemic risk. This article addresses those questions for the practicing veterinarian, focusing on the clinical pharmacology of injectable glucocorticoids, their indications across inflammatory and immune-mediated conditions, the adverse effect profile that governs case selection, and practical monitoring strategies. The discussion excludes intra-articular injection technique and oncology applications, which are covered elsewhere. It also does not address topical or ophthalmic corticosteroid formulations.

The clinical decision to inject a corticosteroid instead of prescribe an oral formulation involves several considerations: owner compliance, gastrointestinal tolerance, the need for rapid onset, and the duration of effect required. Injectable preparations offer predictable bioavailability and bypass first-pass hepatic metabolism, but they cannot be withdrawn quickly if an adverse reaction occurs. This irreversibility of effect once administered is a central feature of the risk discussion that follows. The reader is assumed to be familiar with glucocorticoid receptor biology and the distinction between anti-inflammatory and immunosuppressive dose ranges.

## At a Glance

| Parameter | Clinical Consideration |
|---|---|
| Primary indications | Noninfectious inflammatory conditions, immune-mediated disease, certain dermatopathies, and palliative anti-inflammatory therapy |
| Drug classes | Short-acting (prednisolone, methylprednisolone), intermediate-acting (triamcinolone), long-acting (dexamethasone, betamethasone) |
| Onset of effect | Parenteral absorption is rapid, clinical effect typically within hours to 24 hours depending on formulation |
| Duration of effect | Varies from approximately 24 to 72 hours for short-acting esters to 2 to 4 weeks for repositol formulations |
| Major acute risks | Gastrointestinal ulceration, pancreatitis, hyperglycemia, behavioral changes, polyuria and polydipsia |
| Major chronic risks | Iatrogenic hyperadrenocorticism, hepatopathy, calcinosis cutis, muscle wasting, immunosuppression |
| Monitoring baseline | Body weight, blood pressure, urinalysis, serum biochemistry including glucose and liver enzymes |
| Monitoring follow-up | Clinical response at 7 to 14 days, then reassess need for repeat injection, recheck biochemistry if repeated dosing is planned |
| Contraindications | Active infection, corneal ulceration, poorly controlled diabetes mellitus, pregnancy, known hypersensitivity |

## Pharmacology of Injectable Glucocorticoids

Glucocorticoids exert their effects through intracellular receptor binding that alters gene transcription, a process that takes hours to produce measurable clinical change. The rapid anti-inflammatory actions attributed to corticosteroids, such as reduced vasodilation and decreased neutrophil migration, result from nongenomic mechanisms that occur within minutes to hours. Both pathways contribute to the therapeutic profile of injectable preparations.

The esterification of the corticosteroid molecule determines its solubility and duration of action. Phosphate and succinate esters are water-soluble and rapidly absorbed, producing high peak concentrations with relatively short duration. Acetate and acetonide esters are poorly soluble, forming a depot at the injection site from which drug is released slowly over days to weeks. This distinction matters clinically: a water-soluble preparation of dexamethasone produces effects lasting roughly 24 to 48 hours, whereas dexamethasone phenylpropionate or triamcinolone acetonide can suppress the hypothalamic-pituitary-adrenal axis for 2 to 4 weeks.

Comparative potency guides drug selection. Dexamethasone and betamethasone are approximately 7 to 10 times more potent than prednisolone on a milligram basis, while triamcinolone sits between them. The clinical significance of potency is primarily in dosing accuracy and in anticipating the magnitude of adverse effects. A small dosing error with a high-potency compound produces a proportionally larger physiologic disturbance.

## Mechanisms of Anti-inflammatory Action

The anti-inflammatory effects of corticosteroids arise from multiple coordinated mechanisms. Glucocorticoid receptor activation upregulates the transcription of anti-inflammatory proteins, including lipocortin-1, which inhibits phospholipase A2 and thereby reduces prostaglandin and leukotriene synthesis. Simultaneously, corticosteroids suppress the transcription of pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1, and interleukin-6 through interference with nuclear factor kappa B and activator protein-1 signaling.

These effects reduce vascular permeability, decrease leukocyte extravasation at sites of inflammation, and impair the function of neutrophils, macrophages, and lymphocytes. The clinical consequence is rapid reduction in erythema, swelling, and pain associated with inflammatory lesions. However, the same mechanisms that produce therapeutic benefit also produce the adverse effects discussed later. The therapeutic index is narrow, and the margin between effective anti-inflammatory dosing and clinically significant immunosuppression is smaller than many practitioners assume.

The route of administration does not alter the fundamental pharmacology of the drug. An injectable corticosteroid is not intrinsically safer or more effective than an oral preparation of equivalent potency and duration. The advantages of injection are practical: guaranteed administration, avoidance of gastrointestinal irritation, and the ability to provide sustained effect through depot formulations. The disadvantages are equally practical: no ability to titrate the dose downward if adverse effects emerge, and the potential for injection site reactions.

## Pharmacokinetic Considerations in the Dog

Absorption from an intramuscular or subcutaneous injection site depends on the ester formulation and the vascularity of the tissue. Water-soluble esters are absorbed rapidly and completely. Depot preparations are absorbed slowly, with peak plasma concentrations occurring days after administration and measurable drug levels persisting for weeks. This prolonged exposure is the basis for the extended duration of clinical effect but also for the prolonged suppression of endogenous cortisol production.

Protein binding of corticosteroids in canine plasma is moderate, with albumin and corticosteroid-binding globulin carrying the majority of the drug. Hepatic metabolism via reduction and conjugation produces inactive metabolites excreted in urine. Hepatic dysfunction can prolong drug half-life, and concurrent administration of drugs that induce hepatic enzymes may accelerate clearance. The clinical relevance of these interactions is modest for single injections but becomes important in animals receiving repeated dosing.

The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific pharmacologic guidance that practitioners should consult when selecting a preparation and anticipating its duration of action. The manual emphasizes that individual patient variation in drug metabolism and response is substantial, and that clinical monitoring instead of assumed pharmacokinetic parameters should guide repeat dosing decisions.

## Indications for Injectable Corticosteroids

Injectable corticosteroids are indicated for conditions where rapid, potent anti-inflammatory effect is required and where oral administration is impractical or contraindicated. Common indications in canine practice include acute allergic reactions, immune-mediated hemolytic anemia as part of a multidrug protocol, inflammatory bowel disease where oral absorption is uncertain, and severe dermatologic conditions such as pemphigus foliaceus during initial induction therapy.

The decision to use an injectable instead of oral corticosteroid should be justified by a specific clinical rationale. For example, a dog with severe vomiting that precludes oral medication may require parenteral therapy. A dog with suspected gastrointestinal ulceration may benefit from avoiding oral corticosteroid exposure to the gastric mucosa. Conversely, a dog with chronic atopic dermatitis that requires long-term anti-inflammatory therapy is generally better managed with oral prednisolone at the lowest effective dose, because this allows titration and withdrawal.

The evidence base for specific injectable corticosteroid indications in dogs is largely extrapolated from clinical experience and from human medicine. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains approved labeling information for veterinary corticosteroid products, and practitioners should verify that the chosen product is approved for the intended species and condition. Extralabel use is permitted under the Animal Medicinal Drug Use Clarification Act when a valid veterinarian-client-patient relationship exists, but it requires careful documentation and informed owner consent.

## Contraindications and Case Selection

Absolute contraindications to injectable corticosteroid therapy include active systemic infection, corneal ulceration, and known hypersensitivity to the drug. Relative contraindications require a risk-benefit analysis: diabetes mellitus, hyperadrenocorticism, renal disease, cardiac disease, and pregnancy all warrant caution. In diabetic dogs, the hyperglycemic effect of a single depot injection can persist for weeks and may destabilize insulin requirements. In pregnant bitches, corticosteroids can induce premature parturition, particularly with dexamethasone.

The presence of concurrent infection deserves particular emphasis. Corticosteroids suppress the inflammatory response that contains bacterial and fungal infections, and their use in an animal with undiagnosed sepsis can be fatal. A thorough history and physical examination, including temperature assessment and evaluation of potential infection sources, should precede any corticosteroid injection. Where infection is suspected but not confirmed, the prudent approach is to defer corticosteroid administration until diagnostic testing has excluded an infectious etiology.

The [American Veterinary Medical Association](https://www.avma.org/resources-tools) publishes practice resources that address judicious use of immunomodulatory drugs, and these resources reinforce the principle that corticosteroid therapy should be reserved for conditions where the expected benefit clearly outweighs the risk of immunosuppression and metabolic disturbance.

## Risk-Benefit Assessment Framework

The decision to administer an injectable corticosteroid requires a structured comparison of expected benefit against potential harm for each individual patient. A practical framework weighs three domains: disease characteriztics, patient factors, and treatment history.

**Disease characteriztics.** Acute, self-limiting inflammatory conditions such as flare-ups of allergic dermatitis or immune-mediated polyarthritis may respond rapidly to a single injection. Chronic degenerative conditions, particularly osteoarthritis, present a different calculus. The anti-inflammatory effect is real but temporary, and repeated injections may accelerate cartilage degradation through inhibition of chondrocyte metabolism. For osteoarthritis, the clinician must ask whether the expected duration of relief justifies the cumulative risk. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific guidance on glucocorticoid pharmacology and adverse effect profiles that informs this judgment.

**Patient factors.** Age, body condition, and comorbid disease alter the risk profile substantially. Geriatric dogs with marginal cardiac reserve may decompensate from sodium and water retention. Diabetic dogs experience predictable hyperglycemia that may persist for days to weeks after a single injection. Dogs with hyperadrenocorticism, whether treated or untreated, are at heightened risk of exacerbation. Pregnant bitches warrant particular caution, as glucocorticoids may induce parturition in late gestation.

**Treatment history.** Prior glucocorticoid exposure determines both expected response and risk. A dog that has received repeated injections over months may have suppressed endogenous cortisol production, making withdrawal syndromes more likely. Conversely, a dog that has never received corticosteroids may respond to a lower dose than a glucocorticoid-experienced patient. Document the cumulative dose and interval since last administration before each injection.

| Risk Category | Low-Risk Candidate | High-Risk Candidate | Decision Impact |
|---|---|---|---|
| Metabolic status | Normal glucose, no proteinuria | Diabetes mellitus, hyperadrenocorticism | Avoid or use only with close monitoring |
| Cardiovascular | No known disease | Cardiomyopathy, congestive heart failure | Avoid systemic injection |
| Gastrointestinal | No history of ulceration | Prior GI ulcer, concurrent NSAID use | Avoid concurrent use |
| Infectious status | No active infection | Pyoderma, urinary tract infection, fungal disease | Treat infection first |
| Hepatic function | Normal | Hepatopathy, portosystemic shunt | Reduce dose or avoid |
| Reproductive status | Neutered or non-pregnant | Pregnant, especially late gestation | Avoid in late pregnancy |

## Injectable Corticosteroid Formulations and Duration of Action

Selection of a specific formulation depends on the desired duration of effect, the route of administration, and the condition being treated. The table below summarizes clinically relevant distinctions. Current formulary references must be consulted for specific product availability and dosing guidance, as formulations and concentrations vary by region and manufacturer.

| Formulation | Relative Potency | Duration of Action | Typical Clinical Use | Notable Considerations |
|---|---|---|---|---|
| Dexamethasone (sodium phosphate) | High | Short (hours to 1 day) | Acute inflammatory or allergic crises | Rapid onset, minimal tissue irritation |
| Dexamethasone (aqueous suspension) | High | Intermediate (days) | Inflammatory conditions requiring sustained effect | Slower absorption than phosphate salt |
| Methylprednisolone acetate | Medium | Long (2 to 4 weeks) | Inflammatory skin disease, immune-mediated conditions | Repository formulation, do not use intravenously |
| Triamcinolone acetonide | High | Long (3 to 4 weeks) | Severe inflammatory dermatoses | Potent, prolonged suppression of HPA axis |
| Betamethasone | High | Intermediate to long | Inflammatory conditions | Similar profile to dexamethasone |

The choice between short-acting and repository formulations deserves explicit consideration. Short-acting preparations allow rapid termination of effect if adverse reactions occur. Repository formulations provide convenience but commit the patient to weeks of glucocorticoid exposure that cannot be withdrawn. For first-time administration in a patient with unknown tolerance, a short-acting preparation is the more conservative choice.

## Administration Technique and Protocol Structure

Injectable corticosteroids are administered by intramuscular, subcutaneous, or intravenous routes depending on the formulation. Repository preparations are for intramuscular or subcutaneous use only. Intravenous administration of a particulate suspension carries risk of embolic complications.

**Intramuscular injection.** Select the epaxial muscles, semimembranosus, or semitendinosus. Use a needle of adequate length to reach muscle tissue, accounting for body condition. Aspirate before injection to confirm the needle is not within a vessel. Rotate injection sites with repeated administration.

**Subcutaneous injection.** Acceptable for repository formulations in dogs with adequate skin mobility. The interscapular region is commonly used, though the lateral thorax or flank may be preferred in active dogs to reduce the risk of self-trauma at the site.

**Intravenous injection.** Reserved for water-soluble formulations such as dexamethasone sodium phosphate in acute emergencies. Administer slowly and monitor for adverse reactions during injection.

**Protocol structure.** For acute conditions, a single injection may suffice. For chronic inflammatory conditions requiring repeated administration, establish a minimum interval between injections based on the formulation's duration of action. Document the product name, concentration, dose, route, site, and batch number in the medical record. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains labeling information and adverse event reporting pathways that support pharmacovigilance in practice.

## Monitoring Parameters and Schedule

Monitoring after injectable corticosteroid administration serves three purposes: detection of adverse effects, assessment of therapeutic response, and documentation of recovery from HPA axis suppression.

**Immediate monitoring (first 30 minutes).** Observe for acute reactions including vomiting, diarrhea, or signs of anaphylactoid response. These are uncommon but can occur, particularly with intravenous administration.

**Short-term monitoring (days 1 to 7).** Assess for polyuria, polydipsia, polyphagia, and changes in energy level. These expected pharmacologic effects should resolve as drug levels decline. Persistent or severe signs warrant reevaluation of the dose and formulation choice. In diabetic dogs, measure blood glucose daily during this period and adjust insulin therapy as needed.

**Intermediate monitoring (weeks 1 to 4).** Evaluate the therapeutic response at the expected peak of effect. If the condition has not improved, reconsider the diagnosis instead of simply repeating the injection. Monitor body weight, muscle condition, and skin integrity for signs of glucocorticoid excess.

**Long-term monitoring (repeated injections).** For dogs receiving injections at intervals of weeks to months, perform periodic assessment of liver enzymes, fasting glucose, and urine protein-to-creatinine ratio. The [AVMA practice resources](https://www.avma.org/resources-tools) provide guidance on establishing monitoring protocols for patients on chronic glucocorticoid therapy.

| Monitoring Parameter | Timing | What It Detects | Action Threshold |
|---|---|---|---|
| Body weight | Each visit | Sodium retention, increased appetite | >5% gain from baseline |
| Water intake | Days 1 to 7 | Glucocorticoid-induced polyuria | Intake >100 mL/kg/day |
| Fasting glucose | Days 1 to 3 in diabetics | Hyperglycemia | Glucose >250 mg/dL |
| Liver enzymes | Every 3 to 6 months with repeated use | Hepatopathy | Progressive elevation |
| Urine protein-to-creatinine ratio | Every 6 months with repeated use | Proteinuria, glomerular injury | Ratio >0.5 |
| Skin and coat condition | Each visit | Iatrogenic Cushing syndrome | Alopecia, thin skin, calcinosis cutis |
| Muscle condition score | Each visit | Steroid myopathy | Loss of epaxial or gluteal mass |

## Documentation and Adverse Event Reporting

The medical record should capture the indication, the decision rationale, the specific product and batch number, the dose and route, and the monitoring plan. This documentation supports continuity of care when multiple clinicians see the same patient and provides a basis for evaluating outcomes over time.

Suspected adverse drug events should be reported through the appropriate regulatory pathway. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) accepts adverse event reports for approved animal drugs and provides guidance on reporting requirements. Reporting contributes to the collective understanding of product safety in the broader patient population.

## Special Populations and Situational Adjustments

**Concurrent NSAID therapy.** The combination of systemic corticosteroids and nonsteroidal anti-inflammatory drugs increases the risk of gastrointestinal ulceration and renal injury. Avoid this combination where alternatives exist. If concurrent use is unavoidable, use the lowest effective doses of both agents and monitor for melena, vomiting, and changes in renal parameters.

**Hepatic disease.** Glucocorticoid metabolism occurs primarily in the liver. Dogs with hepatic insufficiency may experience prolonged drug effects and increased risk of hepatotoxicity. Consider alternative anti-inflammatory strategies or use a short-acting formulation at a reduced dose.

**Renal disease.** Sodium and water retention can exacerbate hypertension and proteinuria. In dogs with chronic kidney disease, weigh the anti-inflammatory benefit against the risk of accelerating renal decline. Monitor blood pressure and urine protein excretion if injection is deemed necessary.

**Working and athletic dogs.** Glucocorticoids can cause muscle weakness, particularly with repeated use. This effect may be clinically significant in working dogs, agility competitors, or any dog whose function depends on muscle performance. Discuss this risk with the owner before proceeding.

**Breed considerations.** Brachycephalic breeds may be more sensitive to the respiratory effects of fluid retention. Breeds predisposed to pancreatitis, such as Miniature Schnauzers, warrant caution, as glucocorticoids are a recognized trigger for pancreatitis in susceptible individuals.

**Production and regulatory context.** For dogs that are not companion animals, such as those in breeding programs or research settings, additional considerations apply. International standards for animal health and welfare, such as those published by the [World Organization for Animal Health](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/), may influence treatment decisions and documentation requirements. Clinicians should be aware of applicable regional regulations regarding drug use and withdrawal periods where relevant.

## Recognized Complications and Early Detection

Injectable glucocorticoids produce both predictable pharmacologic effects and idiosyncratic adverse events. The most common complications are iatrogenic hyperadrenocorticism, gastrointestinal injury, and exacerbation of latent infection. Less common but serious events include steroid hepatopathy, pancreatitis, and calcinosis cutis at injection sites.

Iatrogenic hyperadrenocorticism develops after repeated injections of long-acting formulations. Early detection relies on owner-reported polydipsia, polyuria, and polyphagia appearing within days to weeks of injection. Physical examination may reveal abdominal distension, hepatomegaly, or thinning of the skin. Baseline cortisol testing is unreliable during the period of exogenous suppression, so the clinician should document the injection date and formulation when interpreting any subsequent adrenal axis testing. The MSD Veterinary Manual provides species-specific guidance on recognizing and managing glucocorticoid-induced endocrinopathies in dogs ([MSD Veterinary Manual professional reference](https://www.msdvetmanual.com/)).

Gastrointestinal injury ranges from mild vomiting to perforating ulceration. Dogs receiving concurrent nonsteroidal anti-inflammatory drugs are at highest risk, and the combination should be avoided unless the clinical rationale is compelling. Early signs include anorexia, vomiting, melena, and cranial abdominal pain. A dog that develops hematemesis or signs of peritonitis requires immediate hospitalization and surgical evaluation.

Exacerbation of latent infection occurs because glucocorticoids suppress pyrexia, leukocyte trafficking, and tissue repair. A dog with undiagnosed bacterial endocarditis, fungal pneumonia, or urinary tract infection may deteriorate rapidly after injection. Screening for infection should precede injection in any dog with unexplained weight loss, chronic cough, or recurrent fever. The AVMA antimicrobial stewardship resources emphasize that immunosuppressive doses of corticosteroids can mask clinical signs of infection and complicate antimicrobial treatment decisions ([AVMA antimicrobial stewardship guidance](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance)).

## Common Errors and Corrective Action

Less experienced clinicians frequently err in case selection, formulation choice, and follow-up planning.

The first error is injecting a dog with undifferentiated lameness or pruritus before a diagnosis is established. A glucocorticoid injection will suppress clinical signs regardless of cause, which can delay diagnosis of neoplasia, infection, or immune-mediated disease. Corrective action is to require a working diagnosis before injection and to document the rationale in the medical record.

The second error is selecting a long-acting repository formulation for a first presentation or for a condition expected to require repeated dosing. Long-acting esters produce prolonged hypothalamic-pituitary-adrenal suppression and are difficult to reverse if an adverse event occurs. Shorter-acting formulations allow dose titration and earlier reassessment. The FDA Center for Veterinary Medicine maintains labeling information for approved glucocorticoid products, and the label should be consulted for formulation-specific duration data ([FDA CVM animal drug information](https://www.fda.gov/animal-veterinary)).

The third error is failing to schedule a recheck. Injectable corticosteroids are often administered as a single event with no planned follow-up, which delays detection of complications and prevents assessment of response duration. Corrective action is to schedule a recheck at a time interval appropriate to the formulation's expected duration of action.

The fourth error is repeating injections at fixed intervals without reassessing whether the underlying condition remains steroid-responsive. A dog that requires escalating frequency of injections should be re-evaluated for progression of disease or development of steroid resistance.

## Troubleshooting Table

| Observation | Likely Cause | Discriminating Check |
|---|---|---|
| Polyuria and polydipsia within 3 to 7 days of injection | Expected glucocorticoid effect or early iatrogenic hyperadrenocorticism | Compare water intake to baseline, check urine specific gravity, document injection date |
| Vomiting or melena within 7 to 14 days | Glucocorticoid-induced gastrointestinal injury | Fecal occult blood, hematocrit, abdominal ultrasound, review concurrent NSAID use |
| Fever or worsening of presenting signs after initial improvement | Exacerbation of latent infection | Complete blood count, blood culture, thoracic radiographs, urinalysis |
| Poor response or short duration of effect | Incorrect diagnosis, inadequate dose, or rapidly progressive disease | Re-evaluate original diagnosis, consider advanced imaging or biopsy |
| Local alopecia or skin thinning at injection site | Depot formulation effect or calcinosis cutis | Dermatohistopathology if lesion persists beyond 8 weeks |

## Limitations of the Evidence and Divergent Expert Opinion

The evidence base for injectable corticosteroid use in dogs is largely extrapolated from human medicine and from clinical experience instead of from prospective canine trials. Comparative studies of different formulations, dose intervals, and monitoring protocols are scarce. Expert opinion differs on several points.

One point of disagreement is whether repository formulations should ever be used in dogs. Some clinicians avoid them entirely because of prolonged adrenal suppression and difficulty in managing adverse events. Others use them selectively for conditions where owner compliance with oral medication is poor. Neither position is supported by strong comparative data.

A second area of divergence concerns the acceptable frequency of repeat injections. Some authors recommend a minimum interval of three to four weeks between injections of long-acting formulations, while others advocate longer intervals or complete avoidance of repeat dosing. The MSD Veterinary Manual notes that repeated use of long-acting glucocorticoids carries greater risk of iatrogenic hyperadrenocorticism than short courses of oral prednisolone, but specific interval recommendations vary by source ([MSD Veterinary Manual professional reference](https://www.msdvetmanual.com/)).

A third area of uncertainty is the interaction between injectable corticosteroids and concurrent disease. The effects of glucocorticoids on hepatic enzyme induction, insulin sensitivity, and renal perfusion are well described, but the thresholds at which these effects become clinically significant in individual dogs are not precisely defined.

## Referral, Consultation, and Reporting

Referral to a specialist is warranted when the diagnosis remains uncertain after initial evaluation, when the dog fails to respond to an appropriate injection, or when complications require advanced diagnostic capability. Dogs with suspected perforating gastrointestinal ulceration, severe pancreatitis, or uncontrolled diabetes mellitus should be referred for hospitalization and intensive care.

Laboratory involvement is indicated when baseline screening reveals abnormalities that could alter the risk-benefit calculation. A dog with elevated liver enzymes, proteinuria, or abnormal glucose should have those findings investigated before injection. Endocrine consultation is appropriate for dogs with suspected concurrent hyperadrenocorticism or diabetes mellitus.

Regulatory reporting is required when an adverse event is suspected to be related to a product defect, when the event involves an extralabel use that produced harm, or when the event meets the reporting criteria of the relevant regulatory authority. The FDA CVM provides guidance on adverse event reporting for animal drugs, and veterinarians should report serious adverse events even when causality is uncertain ([FDA CVM animal drug information](https://www.fda.gov/animal-veterinary)). International practitioners should consult their own regulatory authority, as reporting requirements differ by jurisdiction. The WOAH terrestrial animal health standards address pharmacovigilance expectations for veterinary medicines in international trade contexts ([WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/)).

## Frequently Asked Questions

### How Do I Choose Between an Injectable Corticosteroid and an Oral Taper When Cost or Client Compliance Is a Concern?

Injectable formulations consolidate treatment into a single visit, which reduces reliance on owner compliance and eliminates the risk of missed oral doses. This advantage matters most when the owner cannot reliably administer twice-daily medication or when follow-up visits are impractical. The trade-off is loss of dose titration. Oral therapy allows step-down adjustment if adverse effects emerge, whereas an injection commits the patient to its duration of action. For chronic conditions such as atopic dermatitis, repeated injections carry cumulative risk, so reserve them for cases where oral administration has failed or is genuinely impossible. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides comparative pharmacology of glucocorticoid formulations to support this decision.

### What Should I Do When the Ideal Injection Site or Needle Size Is Unavailable?

Use the smallest gauge needle that permits reliable aspiration and delivery, typically 22 to 25 gauge for most dogs. If the planned site is compromised by infection, scarring, or patient movement, select an alternate muscle group with comparable blood supply. The gluteal and epaxial muscles are common fallbacks, but confirm the volume you intend to inject is appropriate for the muscle mass. Never substitute intravenous administration for an intramuscular injection unless the formulation label explicitly permits it. When only a longer needle is available, measure the insertion depth against the patient's body condition score. Document any deviation from the standard protocol in the medical record.

### How Should I Document a Corticosteroid Injection to Support Future Clinical Decisions?

Record the exact formulation, concentration, volume, route, and site in the patient record, along with the body weight used for dose calculation. Note the indication, the reason this route was selected over alternatives, and any prior corticosteroid exposure within the preceding six months. Include a recheck plan with specific dates and monitoring parameters. This documentation becomes critical when a second injection is considered, because cumulative exposure drives the risk of iatrogenic hyperadrenocorticism. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains adverse event reporting pathways that complement your clinical records when an unexpected reaction occurs.

### Can I Use Injectable Corticosteroids in a Diabetic Dog That Requires Anti-inflammatory Therapy?

This combination requires explicit caution. Glucocorticoids antagonise insulin action and can precipitate hyperglycemic crisis even at anti-inflammatory doses. If an injectable corticosteroid is unavoidable, inform the owner that insulin requirements will likely rise and that glucose monitoring must intensify. Schedule a glucose curve within three to five days after injection and again near the expected end of drug effect. Prefer the shortest-acting formulation that meets the clinical need. Where an alternative anti-inflammatory class can achieve the goal, use it instead. The [AVMA practice resources](https://www.avma.org/resources-tools) include guidance on managing comorbid endocrine disease that supports this risk discussion.

### How Do I Explain the Risks and Benefits to an Owner Who Expects a "Cortisone Shot" for Chronic Arthritis?

Clarify that injectable corticosteroids can reduce inflammatory pain but do not modify the underlying degenerative process. Explain that repeated injections may accelerate cartilage damage and that multimodal therapy, including weight management and physical rehabilitation, offers more durable benefit. State the expected duration of relief for the specific formulation you intend to use and schedule a recheck before the owner requests another injection. If the owner pressures for immediate relief, acknowledge that a single injection may be appropriate while a long-term plan is built. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) supports this discussion with objective descriptions of glucocorticoid effects on joint tissues.

### What Monitoring Is Required After an Injection in a Dog With Concurrent Cardiac or Renal Disease?

These patients warrant a recheck within seven to ten days instead of waiting for the next scheduled visit. Measure body weight, blood pressure, and serum creatinine or symmetric dimethylarginine if renal disease is known. Glucocorticoid-induced sodium and water retention can decompensate congestive heart failure, so auscult for new murmurs or arrhythmias and ask the owner about cough, tachypnea, or exercise intolerance. For renal patients, polyuria and polydipsia may worsen and accelerate dehydration. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) do not address companion animal therapeutics, but they reinforce the principle that monitoring intensity should match patient risk. Document the monitoring plan before injection and confirm owner understanding.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [No Short-term Clinical Benefit to Bovine Collagen Implant Augmentation in Primary Rotator Cuff Repair: A Matched Retrospective Study.](https://pubmed.ncbi.nlm.nih.gov/39236102/). 2025.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.
- [WOAH Terrestrial Animal Health Code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). WOAH.

## Related Articles

- [Therapeutic Drug Monitoring of Aminoglycosides in Veterinary Patients: Indications and Protocols](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-aminoglycosides)
- [Therapeutic Drug Monitoring of Cyclosporine in Veterinary Dermatology: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-cyclosporine)
- [Therapeutic Drug Monitoring in Veterinary Practice: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-veterinary-practice-indications-interpretation)
- [Therapeutic Drug Monitoring in Epileptic Dogs: Antiepileptic Drug Levels](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-epileptic-dogs-antiepileptic-drug-levels)
- [Corticosteroid Therapy in Canine Atopic Dermatitis: Dosing and Monitoring](/knowledge/veterinary-medicine/clinical-pharmacology/corticosteroid-therapy-canine-atopic-dermatitis-dosing-monitoring)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.